Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $73.45 -2.9%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
CMCT, STEX, PWCM, More
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
CMCT, STEX, PWCM, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics sues Bristol-Myers Squibb over aficamten patent dispute
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
